20 results
6-K
EX-99.1
GLPG
Galapagos NV
13 Jan 20
Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
6:06am
engagement in healthy volunteers. GLPG1205 is an investigational drug and its efficacy and safety have not yet been established.
For information about
6-K
EX-99.1
GLPG
Galapagos NV
1 Nov 18
Current report (foreign)
10:06am
completed several Phase 1 trials, showing favorable findings relating to tolerability, and target engagement in healthy volunteers. GLPG1205 showed
6-K
EX-99.1
GLPG
Galapagos NV
9 Jul 18
Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF
6:10am
. GLPG1205 successfully completed a Phase 1 trial in 2013, showing favorable findings relating to safety and tolerability, and target engagement
6-K
EX-99.1
GLPG
Galapagos NV
27 Jun 18
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
6:01am
have seen clear target engagement in OA patients; now we should be able to answer how this translates to protection against cartilage breakdown," said Dr
6-K
EX-99.1
GLPG
Galapagos NV
19 Jul 18
Current report (foreign)
6:05am
pleased that we can further strengthen our engagement in atopic dermatitis by starting additional trials together with Galapagos, which will be fully
6-K
EX-99.15
rwq0u8
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.2
l3mo9t32
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.5
0lfwt56mo7
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
DRS
EX-10
a6n2kp 7x
6 Feb 15
Draft registration statement
12:00am
6-K
EX-99.3
czsl12qtub3
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
DRS/A
EX-10
09wxud4xqwjj59r0
4 Mar 15
Draft registration statement (amended)
12:00am
20-F
4tgc24
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
fv7ls
4 Mar 15
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next